TY - JOUR
T1 - The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of cyclin D1
AU - McCann, Jennifer L.
AU - Klein, Madeline M.
AU - Leland, Evelyn M.
AU - Law, Emily K.
AU - Brown, William L.
AU - Salamango, Daniel J.
AU - Harris, Reuben S.
N1 - Publisher Copyright:
© 2019 McCann et al.
PY - 2019/8/9
Y1 - 2019/8/9
N2 - Apolipoprotein B mRNA editing enzyme catalytic subunit-like protein 3B (APOBEC3B or A3B), as other APOBEC3 members, is a single-stranded (ss)DNA cytosine deaminase with antiviral activity. A3B is also overexpressed in multiple tumor types, such as carcinomas of the bladder, cervix, lung, head/neck, and breast. A3B generates both dispersed and clustered C-to-T and C-to-G mutations in intrinsically preferred trinucleotide motifs (TCA/TCG/TCT). A3B-catalyzed mutations are likely to promote tumor evolution and cancer progression and, as such, are associated with poor clinical outcomes. However, little is known about cellular processes that regulate A3B. Here, we used a proteomics approach involving affinity purification coupled to MS with human 293T cells to identify cellular proteins that interact with A3B. This approach revealed a specific interaction with cyclin-dependent kinase 4 (CDK4). We validated and mapped this interaction by co-immunoprecipitation experiments. Functional studies and immunofluorescence microscopy experiments in multiple cell lines revealed that A3B is not a substrate for CDK4–Cyclin D1 phosphorylation nor is its deaminase activity modulated. Instead, we found that A3B is capable of disrupting the CDK4-dependent nuclear import of Cyclin D1. We propose that this interaction May favor a more potent antiviral response and simultaneously facilitate cancer mutagenesis.
AB - Apolipoprotein B mRNA editing enzyme catalytic subunit-like protein 3B (APOBEC3B or A3B), as other APOBEC3 members, is a single-stranded (ss)DNA cytosine deaminase with antiviral activity. A3B is also overexpressed in multiple tumor types, such as carcinomas of the bladder, cervix, lung, head/neck, and breast. A3B generates both dispersed and clustered C-to-T and C-to-G mutations in intrinsically preferred trinucleotide motifs (TCA/TCG/TCT). A3B-catalyzed mutations are likely to promote tumor evolution and cancer progression and, as such, are associated with poor clinical outcomes. However, little is known about cellular processes that regulate A3B. Here, we used a proteomics approach involving affinity purification coupled to MS with human 293T cells to identify cellular proteins that interact with A3B. This approach revealed a specific interaction with cyclin-dependent kinase 4 (CDK4). We validated and mapped this interaction by co-immunoprecipitation experiments. Functional studies and immunofluorescence microscopy experiments in multiple cell lines revealed that A3B is not a substrate for CDK4–Cyclin D1 phosphorylation nor is its deaminase activity modulated. Instead, we found that A3B is capable of disrupting the CDK4-dependent nuclear import of Cyclin D1. We propose that this interaction May favor a more potent antiviral response and simultaneously facilitate cancer mutagenesis.
UR - http://www.scopus.com/inward/record.url?scp=85070783176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070783176&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA119.008443
DO - 10.1074/jbc.RA119.008443
M3 - Article
C2 - 31217276
AN - SCOPUS:85070783176
SN - 0021-9258
VL - 294
SP - 12099
EP - 12111
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 32
ER -